A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug
known as baricitinib in participants with moderately to severely active rheumatoid arthritis
who have had an inadequate response to methotrexate therapy.